Stanford researchers have unveiled BRP, a naturally occurring appetite suppressant that could offer weight loss benefits without the side effects of Ozempic.
Stanford Medicine has identified a naturally occurring molecule, known as BRP, that may effectively suppress appetite and contribute to weight reduction in a manner similar to semaglutide, the active ingredient in Ozempic. Notably, initial animal studies suggest BRP avoids several adverse effects commonly associated with existing treatments, such as nausea, constipation, and significant muscle loss.
Understanding BRP and its Mechanism
The BRP molecule operates through a related yet distinct metabolic pathway, targeting a specific group of neurons in the hypothalamus. This precision could present an advantageous alternative for appetite and weight management.
Dr. Katrin Svensson, an assistant professor of pathology, pointed out the differences between semaglutide and BRP: "The receptors targeted by semaglutide are distributed throughout the body - in the brain, gut, pancreas, and other tissues. This wide reach leads to diverse effects, such as slower digestion and reduced blood sugar levels. Conversely, BRP appears to focus its effects primarily in the hypothalamus, the critical region for appetite and energy regulation."
The Importance of AI in Discovery
Significantly, the discovery of BRP relied heavily on artificial intelligence (AI). Researchers utilized AI to sift through a class of molecules known as prohormones, which are inactive precursors requiring enzymatic processing to become functional peptides.
Prohormones are complex, and traditional methods of identifying biologically active peptides can yield vast datasets, as genuine peptide hormones are relatively sparse within a sea of other fragments generated during protein metabolism. Hence, finding these key peptides presents a considerable challenge.
The research team focused on the enzyme prohormone convertase 1/3, known for its role in obesity regulation within human physiology. By thinking outside conventional methods, the team developed an algorithm named Peptide Predictor, which scanned through the human protein-coding genome to pinpoint peptide-coding sites that are typically cleaved by the enzyme.
This AI-driven approach allowed them to narrow down a list of 373 prohormones, greatly enhancing the manageability of their subsequent investigations.
Identifying BRP's Unique Characteristics
Peptide Predictor estimated that these identified prohormones could yield 2,683 distinct peptides. Focusing on those most likely to have central nervous system effects led to the selection of 100 potential candidates for laboratory testing.
Notable among these was a small 12-amino-acid peptide that outperformed others, generating tenfold neuronal activation compared to controls. This peptide was subsequently named BRP, derived from its parent prohormone BPM/retinoic acid inducible neural specific 2 (BRINP2).
Preliminary Animal Testing and Results
BRP's efficacy was evaluated in both lean mice and minipigs, the latter being particularly significant due to their closer metabolic parallels to humans. After intramuscular injections administered prior to feeding, food intake observed a dramatic decrease—up to 50%—in both test subjects.
When injected daily into obese mice over 14 days, those treated with BRP lost an average of 3 grams, predominantly from body fat, while control subjects gained weight. Further studies noted that the treated mice demonstrated improved glucose and insulin tolerance, highlighting potential metabolic benefits.
Interestingly, behavioral assessments indicated no significant differences between treated and untreated subjects regarding movement or anxiety, nor in fecal production. This absence of changes is particularly noteworthy as semaglutide is often associated with digestive issues like constipation.
The Future of BRP and Its Clinical Trials
The research team's findings suggest that BRP might reduce appetite through a more targeted biological pathway compared to GLP-1 and semaglutide. However, it’s essential to recognize that these observations remain at the preclinical stage.
Next steps involve identifying the receptors that interact with BRP, which will provide insights into how this peptide influences appetite and metabolism. Additionally, addressing the stability of BRP in the body is vital, as small peptides tend to degrade rapidly, limiting their therapeutic potential.
Dr. Svensson expressed optimism about the clinical applications of BRP, stating, "The scarcity of effective obesity treatments has been a longstanding concern. We've yet to see anything like semaglutide's results with appetite suppression and weight loss. Our eagerness to determine its safety and efficacy in humans is palpable."
This research has connections beyond Stanford, with contributions from the University of California, Berkeley; the University of Minnesota; and the University of British Columbia, all furthering the exploration of metabolic disorders.
The study, which received funding from various prestigious institutions including the National Institutes of Health and Stanford Bio-X, is a pivotal advancement in metabolic research.
BRP represents a promising avenue for future obesity therapies, and the pursuit of its clinical application could hold significant implications for weight management in humans.
Discussion
Sign in to join the discussion.